Compare Regeneron Pharmaceuticals Inc (REGN) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vistra Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Vistra Corp trades at $151.01 (market cap $50.11B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Vistra Corp pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| REGN | VST | |
|---|---|---|
Market Cap | $83.43B | $50.11B |
Sector | Health | Technology |
52-Week High | $852.03 | $217.92 |
52-Week Low | $555.51 | $134.71 |
Enterprise Value | $78.14B | $72.05B |
Dividend Yield | 0.46% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical signal and strong analyst support. The stock shows mixed quarterly earnings but projects significant revenue and net income growth into 2026. Recent news highlights CEO and institutional buying, long-term power agreements with tech giants, and a consensus price target of $228.40, suggesting substantial upside potential from current levels.
The outlook is positive, driven by robust power demand, strategic partnerships, and a diversified generation fleet. Key risks include regulatory uncertainty and earnings volatility. With 91% of analysts rating it a buy and insider confidence, VST presents a compelling opportunity for growth-oriented investors, though market fluctuations and execution risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
